argenx SE (NASDAQ:ARGX) Shares Sold by Candriam S.C.A.

Candriam S.C.A. trimmed its holdings in shares of argenx SE (NASDAQ:ARGX) by 6.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,210 shares of the company’s stock after selling 3,208 shares during the period. Candriam S.C.A. owned approximately 0.08% of argenx worth $29,649,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. US Bancorp DE lifted its position in argenx by 7.8% during the third quarter. US Bancorp DE now owns 4,350 shares of the company’s stock valued at $2,358,000 after purchasing an additional 316 shares during the period. Janney Montgomery Scott LLC raised its stake in shares of argenx by 201.2% during the 3rd quarter. Janney Montgomery Scott LLC now owns 2,072 shares of the company’s stock valued at $1,123,000 after buying an additional 1,384 shares during the last quarter. Keudell Morrison Wealth Management acquired a new position in shares of argenx in the 3rd quarter valued at about $207,000. Assetmark Inc. boosted its stake in shares of argenx by 8.3% in the third quarter. Assetmark Inc. now owns 7,769 shares of the company’s stock worth $4,211,000 after buying an additional 598 shares during the last quarter. Finally, TimesSquare Capital Management LLC grew its holdings in argenx by 8.8% during the third quarter. TimesSquare Capital Management LLC now owns 109,490 shares of the company’s stock worth $59,352,000 after acquiring an additional 8,840 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Down 3.7 %

argenx stock opened at $613.18 on Friday. The company has a fifty day simple moving average of $642.47 and a 200-day simple moving average of $592.89. The firm has a market capitalization of $37.26 billion, a price-to-earnings ratio of -696.80 and a beta of 0.58. argenx SE has a 52-week low of $349.86 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. On average, research analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on ARGX. Robert W. Baird upped their price objective on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday. Truist Financial reissued a “buy” rating and set a $700.00 price target (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. HC Wainwright upped their price objective on shares of argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft cut argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $662.83.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.